WhiteSwell Announces New Data Supporting Acute Decompensated Heart Failure Treatment with eLym System
WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive data from 21 patients treated in its DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented at the Technology and Heart Failure Therapeutics (THT) meeting in Boston by Jan Biegus, M.D., deputy scientific director at the Institute of Heart Diseases at Wroclaw Medical University in Poland.
WhiteSwell Expands Leadership Team with Key Appointments
WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), today announced the appointments of Ric Cote to its board of directors and Sergio Shkurovich as vice president of clinical affairs.
WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study
WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented by William Abraham, M.D., professor of medicine, physiology, and cell biology at The Ohio State University Wexner Medical Center, at the Technology and Heart Failure Therapeutics (THT) conference today in Boston.
WhiteSwell Announces Successful Treatment of Acute Decompensated Heart Failure Patients in its Early Feasibility DELTA-HF Study
WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive initial results from its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System. The data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.
WhiteSwell Adds Experienced Executives to its Senior Management Team
WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today the appointment of Linda Nelson as Vice President of Clinical and Martin Keegan as Vice President of Technical Operations.
